Benini L, Cavallini G, Zordan D, Rizzotti P, Rigo L, Brocco G, Perobelli L, Zanchetta M, Pederzoli P, Scuro L A
Medical Clinic, University of Verona, Italy.
Pancreas. 1988;3(1):61-6. doi: 10.1097/00006676-198802000-00011.
We measured in 193 patients, admitted to our wards for symptoms and signs suggestive of pancreatic or digestive malignancy, the serum levels of five tumor-associated antigens (CA 19-9, CA 50, CA 125, TPA, CEA) and we evaluated their diagnostic accuracy both when used alone and in combination. For CA 19-9 and CA 50 a sensitivity for pancreatic cancer as high as 92 and 88%, respectively, and specificity of 91.8% were found. A lower sensitivity vs. pancreatic cancer was found for the other tumor markers, and vs. the other digestive and nondigestive malignancies for all tumor markers (apart for CA 19-9 and CA 50 vs. biliary carcinomas). As for the combined assays, the best figures were found vs. pancreatic cancer for CA 19-9 plus CA 50, CA 50 plus CEA, CA 50 plus CA 125; a sensitivity by far worse vs. the other gastrointestinal cancers was found for all the possible combinations. We conclude that in selected symptomatic patients some tumor-marker determinations can be useful in identifying those with a high probability of harboring a pancreatic cancer, to be further studied or operated upon. The clinical relevance of this in patients already symptomatic is at present unclear.
我们对193名因出现提示胰腺或消化系恶性肿瘤的症状和体征而入住我们病房的患者，检测了5种肿瘤相关抗原（CA 19-9、CA 50、CA 125、TPA、CEA）的血清水平，并评估了它们单独使用和联合使用时的诊断准确性。对于CA 19-9和CA 50，发现其对胰腺癌的敏感性分别高达92%和88%，特异性为91.8%。对于其他肿瘤标志物，发现其对胰腺癌的敏感性较低，对于所有肿瘤标志物（CA 19-9和CA 50对胆管癌除外），对其他消化系和非消化系恶性肿瘤的敏感性也较低。至于联合检测，CA 19-9加CA 50、CA 50加CEA、CA 50加CA 125对胰腺癌的检测结果最佳；对于所有可能的组合，发现其对其他胃肠道癌症的敏感性要差得多。我们得出结论，在选定的有症状患者中，一些肿瘤标志物检测有助于识别那些极有可能患有胰腺癌的患者，以便进一步研究或进行手术。目前尚不清楚这在已经出现症状的患者中的临床意义。
